{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:25:50Z","timestamp":1790889950890,"version":"4.1.0"},"reference-count":134,"publisher":"MDPI AG","issue":"13","license":[{"start":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T00:00:00Z","timestamp":1719360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>The long-term survivorship of patients diagnosed with cancer has improved due to accelerated detection and rapidly evolving cancer treatment strategies. As such, the evaluation and management of cancer therapy related complications has become increasingly important, including cardiovascular complications. These have been captured under the umbrella term \u201ccardiotoxicity\u201d and include left ventricular dysfunction and heart failure, acute coronary syndromes, valvular abnormalities, pericardial disease, arrhythmia, myocarditis, and vascular complications. These complications add to the burden of cardiovascular disease (CVD) or are risk factors patients with cancer treatment are presenting with. Of note, both pre- and newly developing CVD is of prognostic significance, not only from a cardiovascular perspective but also overall, potentially impacting the level of cancer therapy that is possible. Currently, there are varying recommendations and practices regarding CVD risk assessment and mitigating strategies throughout the cancer continuum. This article provides an overview on this topic, in particular, the role of cardiac imaging in the care of the patient with cancer. Furthermore, it summarizes the current evidence on the spectrum, prevention, and management of chemotherapy-related adverse cardiac effects.<\/jats:p>","DOI":"10.3390\/jcm13133714","type":"journal-article","created":{"date-parts":[[2024,6,26]],"date-time":"2024-06-26T09:29:33Z","timestamp":1719394173000},"page":"3714","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Chemotherapy Related Cardiotoxicity Evaluation\u2014A Contemporary Review with a Focus on Cardiac Imaging"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6459-9767","authenticated-orcid":false,"given":"Isabel G.","family":"Scalia","sequence":"first","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2119-5578","authenticated-orcid":false,"given":"Bashaer","family":"Gheyath","sequence":"additional","affiliation":[{"name":"Department of Imaging, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balaji K.","family":"Tamarappoo","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Banner University Medical Center, The University of Arizona College of Medicine, Phoenix, AZ 85004, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Moudgil","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Heart and Vascular Institute, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5587-4790","authenticated-orcid":false,"given":"James","family":"Otton","sequence":"additional","affiliation":[{"name":"Clinical School, St. Vincent\u2019s Hospital, UNSW, Sydney, NSW 2010, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4695-8436","authenticated-orcid":false,"given":"Milagros","family":"Pereyra","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hema","family":"Narayanasamy","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Larsen","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Herrmann","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN 55905, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7081-4286","authenticated-orcid":false,"given":"Reza","family":"Arsanjani","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chadi","family":"Ayoub","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Mayo Clinic, Phoenix, AZ 85054, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,6,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1158\/1055-9965.EPI-11-0729","article-title":"Cancer Survivors: A Booming Population","volume":"20","author":"Parry","year":"2011","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaccao.2021.01.011","article-title":"BSE and BCOS Guideline for Transthoracic Echocardiographic Assessment of Adult Cancer Patients Receiving Anthracyclines and\/or Trastuzumab","volume":"3","author":"Dobson","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S0140-6736(13)62225-4","article-title":"Cancer survival: Global surveillance will stimulate health policy and improve equity","volume":"383","author":"Coleman","year":"2014","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1002\/ejhf.1957","article-title":"Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: A position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)","volume":"22","author":"Celutkiene","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American society of clinical oncology clinical practice guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/j.jacc.2022.08.743","article-title":"Advances in Multimodality Imaging in Cardio-Oncology: JACC State-of-the-Art Review","volume":"80","author":"Baldassarre","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.recesp.2020.11.014","article-title":"Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC","volume":"74","author":"Mitroi","year":"2021","journal-title":"Rev. Esp. Cardiol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.mayocp.2014.05.013","article-title":"Evaluation and management of patients with heart disease and cancer: Cardio-oncology","volume":"89","author":"Herrmann","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1200\/JCO.2017.77.4414","article-title":"Association of Cardiovascular Risk Factors With Cardiac Events and Survival Outcomes Among Patients With Breast Cancer Enrolled in SWOG Clinical Trials","volume":"36","author":"Hershman","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.echo.2014.07.012","article-title":"Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: A report from the American society of echocardiography and the European association of cardiovascular imaging","volume":"27","author":"Plana","year":"2014","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/eurheartj\/ehab674","article-title":"Defining cardiovascular toxicities of cancer therapies: An International Cardio-Oncology Society (IC-OS) consensus statement","volume":"43","author":"Herrmann","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.15420\/cfr.2018.25.1","article-title":"Subclinical Left Ventricular Dysfunction During Chemotherapy","volume":"5","author":"Nicol","year":"2019","journal-title":"Card. Fail. Rev."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.jacc.2009.03.095","article-title":"Anthracycline-Induced Cardiomyopathy: Clinical Relevance and Response to Pharmacologic Therapy","volume":"55","author":"Cardinale","year":"2010","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1200\/JCO.2005.05.827","article-title":"Type II chemotherapy-related cardiac dysfunction: Time to recognize a new entity","volume":"23","author":"Ewer","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1177\/2047487319846715","article-title":"Risk prediction tools in cardiovascular disease prevention: A report from the ESC Prevention of CVD Programme led by the European Association of Preventive Cardiology (EAPC) in collaboration with the Acute Cardiovascular Care Association (ACCA) and the Association of Cardiovascular Nursing and Allied Professions (ACNAP)","volume":"26","author":"Rossello","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.118.037934","article-title":"Genetic Variants Associated With Cancer Therapy-Induced Cardiomyopathy","volume":"140","author":"Kim","year":"2019","journal-title":"Circulation"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1093\/jnci\/djp440","article-title":"Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention","volume":"102","author":"Albini","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/eurjpc\/zwaa034","article-title":"Cardiovascular risk factors during cancer treatment. Prevalence and prognostic relevance: Insights from the CARDIOTOX registry","volume":"29","author":"Rodriguez","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","article-title":"2021 ESC Guidelines on cardiovascular disease prevention in clinical practice","volume":"42","author":"Visseren","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Suntheralingam, S., Fan, C.S., Calvillo-Arguelles, O., Abdel-Qadir, H., Amir, E., and Thavendiranathan, P. (2022). Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer. J. Clin. Med., 11.","DOI":"10.3390\/jcm11030847"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e000472","DOI":"10.1161\/JAHA.113.000472","article-title":"Risk prediction model for heart failure and cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"3","author":"Ezaz","year":"2014","journal-title":"J. Am. Heart Assoc."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1161\/CIR.0000000000001174","article-title":"Cardiovascular Imaging in Contemporary Cardio-Oncology: A Scientific Statement From the American Heart Association","volume":"148","author":"Addison","year":"2023","journal-title":"Circulation"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/ejhf.2017","article-title":"Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: A position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology","volume":"22","author":"Pudil","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1200\/JCO.19.00231","article-title":"Prospective Study of Cardiac Events During Proteasome Inhibitor Therapy for Relapsed Multiple Myeloma","volume":"37","author":"Cornell","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1136\/heartjnl-2015-307848","article-title":"Cardiovascular biomarkers in patients with cancer and their association with all-cause mortality","volume":"101","author":"Pavo","year":"2015","journal-title":"Heart"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1093\/eurheartj\/ehaa006","article-title":"Classification, prevalence, and outcomes of anticancer therapy-induced cardiotoxicity: The CARDIOTOX registry","volume":"41","author":"Lyon","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1161\/01.CIR.0000130926.51766.CC","article-title":"Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy","volume":"109","author":"Cardinale","year":"2004","journal-title":"Circulation"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.3322\/caac.21341","article-title":"Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management","volume":"66","author":"Curigliano","year":"2016","journal-title":"CA Cancer J. Clin."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijcard.2010.03.003","article-title":"Cardiac side-effects of cancer chemotherapy","volume":"144","author":"Monsuez","year":"2010","journal-title":"Int. J. Cardiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","article-title":"Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management","volume":"53","author":"Yeh","year":"2009","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJM200103153441101","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0910383","article-title":"Adjuvant trastuzumab in HER2-positive breast cancer","volume":"365","author":"Slamon","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1182\/bloodadvances.2017015545","article-title":"Analysis of carfilzomib cardiovascular safety profile across relapsed and\/or refractory multiple myeloma clinical trials","volume":"2","author":"Chari","year":"2018","journal-title":"Blood Adv."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: An observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Jimenez-Alejandre, R., Ruiz-Fernandez, I., and Martin, P. (2022). Pathophysiology of Immune Checkpoint Inhibitor-Induced Myocarditis. Cancers, 14.","DOI":"10.3390\/cancers14184494"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e16","DOI":"10.15420\/aer.2023.04","article-title":"Ventricular Arrhythmia in Cancer Patients: Mechanisms, Treatment Strategies and Future Avenues","volume":"12","author":"Agarwal","year":"2023","journal-title":"Arrhythm. Electrophysiol. Rev."},{"key":"ref_45","first-page":"2","article-title":"Management of atrial fibrillation in patients taking targeted cancer therapies","volume":"3","author":"Asnani","year":"2017","journal-title":"Cardiooncology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-022-06753-7","article-title":"The association of trastuzumab with atrial fibrillation and heart failure in breast cancer patients in routine clinical practice: A population-based propensity score matching and competing risk model analysis","volume":"198","author":"Wu","year":"2023","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s43044-023-00331-y","article-title":"Effects of trastuzumab and trastuzumab emtansine on corrected QT interval and left ventricular ejection fraction in patients with metastatic (HER2+) breast cancer","volume":"75","author":"Levicki","year":"2023","journal-title":"Egypt. Heart J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e005443","DOI":"10.1161\/CIRCEP.117.005443","article-title":"Cancer Treatment-Induced Arrhythmias: Focus on Chemotherapy and Targeted Therapies","volume":"10","author":"Buza","year":"2017","journal-title":"Circ. Arrhythm. Electrophysiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.jacc.2013.11.026","article-title":"Insights into onco-cardiology: Atrial fibrillation in cancer","volume":"63","author":"Farmakis","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ejim.2020.08.004","article-title":"Patterns of anticoagulation for atrial fibrillation in cancer patients referred to cardio-oncological evaluation","volume":"82","author":"Toma","year":"2020","journal-title":"Eur. J. Intern. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/ejhf.1168","article-title":"Long-term effect of epirubicin on incidence of heart failure in women with breast cancer: Insight from a randomized clinical trial","volume":"20","author":"Banke","year":"2018","journal-title":"Eur. J. Heart Fail."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1093\/annonc\/mdf170","article-title":"Myocardial injury revealed by plasma troponin I in breast cancer treated with high-dose chemotherapy","volume":"13","author":"Cardinale","year":"2002","journal-title":"Ann. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.jacc.2013.10.061","article-title":"Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab","volume":"63","author":"Ky","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1002\/ejhf.1631","article-title":"Troponins and brain natriuretic peptides for the prediction of cardiotoxicity in cancer patients: A meta-analysis","volume":"22","author":"Michel","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1161\/CIRCULATIONAHA.123.062405","article-title":"Cardiomuscular Biomarkers in the Diagnosis and Prognostication of Immune Checkpoint Inhibitor Myocarditis","volume":"148","author":"Lehmann","year":"2023","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1373\/clinchem.2005.050153","article-title":"N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: A marker predictive of cardiac dysfunction?","volume":"51","author":"Sandri","year":"2005","journal-title":"Clin. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","unstructured":"Skovgaard, D., Hasbak, P., and Kjaer, A. (2014). BNP predicts chemotherapy-related cardiotoxicity and death: Comparison with gated equilibrium radionuclide ventriculography. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0096736"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.pcad.2014.05.002","article-title":"Cardio-oncology: Role of echocardiography","volume":"57","author":"Villarraga","year":"2014","journal-title":"Prog. Cardiovasc. Dis."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.echo.2013.12.005","article-title":"Analysis of left ventricular volumes and function: A multicenter comparison of cardiac magnetic resonance imaging, cine ventriculography, and unenhanced and contrast-enhanced two-dimensional and three-dimensional echocardiography","volume":"27","author":"Hoffmann","year":"2014","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Slawinski, G., Hawryszko, M., Lizewska-Springer, A., Nabialek-Trojanowska, I., and Lewicka, E. (2023). Global Longitudinal Strain in Cardio-Oncology: A Review. Cancers, 15.","DOI":"10.3390\/cancers15030986"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1016\/j.jacc.2014.01.073","article-title":"Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: A systematic review","volume":"63","author":"Thavendiranathan","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.echo.2013.02.008","article-title":"Independent and Incremental Value of Deformation Indices for Prediction of Trastuzumab-Induced Cardiotoxicity","volume":"26","author":"Negishi","year":"2013","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3396","DOI":"10.1016\/j.ejca.2013.06.046","article-title":"Left ventricular systolic function in HER2\/neu negative breast cancer patients treated with anthracycline chemotherapy: A comparative analysis of left ventricular ejection fraction and myocardial strain imaging over 12 months","volume":"49","author":"Stoodley","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.clon.2022.05.001","article-title":"Global Longitudinal Strain for the Early Detection of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis","volume":"34","author":"Cocco","year":"2022","journal-title":"Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1001\/jamacardio.2019.2952","article-title":"Assessment of Prognostic Value of Left Ventricular Global Longitudinal Strain for Early Prediction of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-analysis","volume":"4","author":"Oikonomou","year":"2019","journal-title":"JAMA Cardiol."},{"key":"ref_66","first-page":"4","article-title":"Baseline global longitudinal strain predictive of anthracycline-induced cardiotoxicity","volume":"7","author":"Chitturi","year":"2021","journal-title":"Cardiooncology"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"e014419","DOI":"10.1161\/CIRCIMAGING.122.014419","article-title":"Myocardial Work in Echocardiography","volume":"16","author":"Marzlin","year":"2023","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1016\/j.jcmg.2019.05.028","article-title":"A Roadmap to Assess Myocardial Work: From Theory to Clinical Practice","volume":"12","author":"Kostyukevich","year":"2019","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jcmg.2022.02.027","article-title":"Diagnostic and Prognostic Value of Myocardial Work Indices for Identification of Cancer Therapy-Related Cardiotoxicity","volume":"15","author":"Thampinathan","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"100818","DOI":"10.1016\/j.cpcardiol.2021.100818","article-title":"Subclinical Cardiotoxicity: The Emerging Role of Myocardial Work and Other Imaging Techniques","volume":"46","author":"Manno","year":"2021","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.jcmg.2022.03.021","article-title":"Myocardial Work in Cardio-Oncology: How Well Does it Work?","volume":"15","author":"Argulian","year":"2022","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e002661","DOI":"10.1161\/CIRCHEARTFAILURE.115.002661","article-title":"Cancer Therapy-Related Cardiac Dysfunction and Heart Failure: Part 1: Definitions, Pathophysiology, Risk Factors, and Imaging","volume":"9","author":"Bloom","year":"2016","journal-title":"Circ. Heart Fail."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1016\/j.echo.2012.09.001","article-title":"Use of Echocardiography to Evaluate the Cardiac Effects of Therapies Used in Cancer Treatment: What Do We Know?","volume":"25","author":"Oreto","year":"2012","journal-title":"J. Am. Soc. Echocardiogr."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s11936-014-0296-3","article-title":"Cardiac complications of chemotherapy: Role of imaging","volume":"16","author":"Tan","year":"2014","journal-title":"Curr. Treat. Options Cardiovasc. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaccao.2020.01.007","article-title":"Early Detection and Prediction of Anthracycline-Induced Right Ventricular Cardiotoxicity by 3-Dimensional Echocardiography","volume":"2","author":"Zhao","year":"2020","journal-title":"JACC CardioOncol."},{"key":"ref_76","first-page":"675","article-title":"Echocardiography In the Prediction of Atrial Fibrillation Recurrence: A Review","volume":"5","author":"Caputo","year":"2012","journal-title":"J. Atr. Fibrillation"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4250\/jcu.2011.19.2.51","article-title":"Role of echocardiography in atrial fibrillation","volume":"19","author":"Kim","year":"2011","journal-title":"J. Cardiovasc. Ultrasound"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1093\/europace\/eux013","article-title":"Left atrial volume predicts atrial fibrillation recurrence after radiofrequency ablation: A meta-analysis","volume":"20","author":"Njoku","year":"2018","journal-title":"Europace"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e007023","DOI":"10.1161\/CIRCIMAGING.117.007023","article-title":"Left Atrial Strain: A Must or a Plus for Routine Clinical Practice?","volume":"10","author":"Donal","year":"2017","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Motoc, A., Luchian, M.L., Scheirlynck, E., Roosens, B., Chameleva, H., Gevers, M., Galloo, X., von Kemp, B., Ramak, R., and Sieira, J. (2021). Incremental value of left atrial strain to predict atrial fibrillation recurrence after cryoballoon ablation. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0259999"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1111\/echo.13184","article-title":"Clinical Relevance of Left Atrial Strain to Predict Recurrence of Atrial Fibrillation after Catheter Ablation: A Meta-Analysis","volume":"33","author":"Ma","year":"2016","journal-title":"Echocardiography"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Di Lisi, D., Moreo, A., Casavecchia, G., Cadeddu Dessalvi, C., Bergamini, C., Zito, C., Madaudo, C., Madonna, R., Cameli, M., and Novo, G. (2023). Atrial Strain Assessment for the Early Detection of Cancer Therapy-Related Cardiac Dysfunction in Breast Cancer Women (The STRANO STUDY: Atrial Strain in Cardio-Oncology). J. Clin. Med., 12.","DOI":"10.3390\/jcm12227127"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.mric.2019.04.001","article-title":"Assessment of Cardiotoxicity of Cancer Chemotherapy: The Value of Cardiac MR Imaging","volume":"27","author":"Quinaglia","year":"2019","journal-title":"Magn. Reson. Imaging Clin. N. Am."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Wei, X., Lin, L., Zhang, G., and Zhou, X. (2022). Cardiovascular Magnetic Resonance Imaging in the Early Detection of Cardiotoxicity Induced by Cancer Therapies. Diagnostics, 12.","DOI":"10.3390\/diagnostics12081846"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jaccao.2021.04.011","article-title":"Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization","volume":"3","author":"Ferrari","year":"2021","journal-title":"JACC CardioOncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.hfc.2020.08.009","article-title":"The Role of Cardiovascular MRI in Cardio-Oncology","volume":"17","author":"Bottinor","year":"2021","journal-title":"Heart Fail. Clin."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"e003584","DOI":"10.1161\/CIRCIMAGING.115.003584","article-title":"Characterization of the Changes in Cardiac Structure and Function in Mice Treated With Anthracyclines Using Serial Cardiac Magnetic Resonance Imaging","volume":"9","author":"Farhad","year":"2016","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e15226","DOI":"10.1016\/j.heliyon.2023.e15226","article-title":"Role of advanced cardiovascular imaging in chemotherapy-induced cardiotoxicity","volume":"9","author":"Cannizzaro","year":"2023","journal-title":"Heliyon"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1002\/ehf2.12277","article-title":"Native myocardial T1 time can predict development of subsequent anthracycline-induced cardiomyopathy","volume":"5","author":"Muehlberg","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1038\/s41598-017-02627-x","article-title":"Early Detection and Serial Monitoring of Anthracycline-Induced Cardiotoxicity Using T1-mapping Cardiac Magnetic Resonance Imaging: An Animal Study","volume":"7","author":"Hong","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.jacc.2018.11.046","article-title":"Serial Magnetic Resonance Imaging to Identify Early Stages of Anthracycline-Induced Cardiotoxicity","volume":"73","author":"Lobo","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jacc.2012.09.035","article-title":"Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: Application to patients undergoing cancer chemotherapy","volume":"61","author":"Thavendiranathan","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1007\/s12350-018-1293-9","article-title":"Cardiac MRI for the evaluation of oncologic cardiotoxicity","volume":"25","author":"Loffler","year":"2018","journal-title":"J. Nucl. Cardiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1532-429X-10-5","article-title":"Delayed contrast enhancement cardiac magnetic resonance imaging in trastuzumab induced cardiomyopathy","volume":"10","author":"Lytwyn","year":"2008","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/CIRCIMAGING.114.002217","article-title":"Longitudinal Assessment of Concurrent Changes in Left Ventricular Ejection Fraction and Left Ventricular Myocardial Tissue Characteristics After Administration of Cardiotoxic Chemotherapies Using T1-Weighted and T2-Weighted Cardiovascular Magnetic Resonan","volume":"7","author":"Jordan","year":"2014","journal-title":"Circulation. Cardiovasc. Imaging"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e014283","DOI":"10.1161\/CIRCIMAGING.122.014283","article-title":"Cardiac Magnetic Resonance Imaging Techniques and Applications for Pericardial Diseases","volume":"15","author":"Wang","year":"2022","journal-title":"Circ. Cardiovasc. Imaging"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1093\/eurheartj\/ehw022","article-title":"Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): A 2 \u00d7 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol","volume":"37","author":"Gulati","year":"2016","journal-title":"Eur. Heart J."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.amjcard.2012.07.040","article-title":"Left ventricular mass in patients with a cardiomyopathy after treatment with anthracyclines","volume":"110","author":"Neilan","year":"2012","journal-title":"Am. J. Cardiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1067\/mhj.2001.115436","article-title":"Subclinical cardiotoxic effects of anthracyclines as assessed by magnetic resonance imaging\u2014A pilot study","volume":"141","author":"Wassmuth","year":"2001","journal-title":"Am. Heart J."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Taylor, A.J., Cerqueira, M., Hodgson, J.M., Mark, D., Min, J., O\u2019Gara, P., Rubin, G.D., Kramer, C.M., Taylor, A.J., and Berman, D. (2010). ACCF\/SCCT\/ACR\/AHA\/ASE\/ASNC\/NASCI\/SCAI\/SCMR 2010 Appropriate Use Criteria for Cardiac Computed Tomography. J. Cardiovasc. Comput. Tomogr., 4.","DOI":"10.1016\/j.jcct.2010.11.001"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/s12968-017-0348-4","article-title":"Accuracy of left ventricular ejection fraction by contemporary multiple gated acquisition scanning in patients with cancer: Comparison with cardiovascular magnetic resonance","volume":"19","author":"Huang","year":"2017","journal-title":"J. Cardiovasc. Magn. Reson."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11897-022-00544-3","article-title":"LVEF by Multigated Acquisition Scan Compared to Other Imaging Modalities in Cardio-Oncology: A Systematic Review","volume":"19","author":"Printezi","year":"2022","journal-title":"Curr. Heart Fail. Rep."},{"key":"ref_103","first-page":"170","article-title":"Scintigraphic Techniques for Early Detection of Cancer Treatment-Induced Cardiotoxicity","volume":"41","author":"Bellersen","year":"2013","journal-title":"J. Nucl. Med. Technol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2404","DOI":"10.1161\/CIRCULATIONAHA.116.021612","article-title":"Nonbiopsy Diagnosis of Cardiac Transthyretin Amyloidosis","volume":"133","author":"Gillmore","year":"2016","journal-title":"Circulation"},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Kamel, M.A., Abbas, M.T., Kanaan, C.N., Awad, K.A., Baba Ali, N., Scalia, I.G., Farina, J.M., Pereyra, M., Mahmoud, A.K., and Steidley, D.E. (2024). How Artificial Intelligence Can Enhance the Diagnosis of Cardiac Amyloidosis: A Review of Recent Advances and Challenges. J. Cardiovasc. Dev. Dis., 11.","DOI":"10.3390\/jcdd11040118"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Rapezzi","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1093\/eurheartj\/ehy267","article-title":"The performance of non-invasive tests to rule-in and rule-out significant coronary artery stenosis in patients with stable angina: A meta-analysis focused on post-test disease probability","volume":"39","author":"Knuuti","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.jcct.2022.09.002","article-title":"Cardiac computed tomographic imaging in cardio-oncology: An expert consensus document of the Society of Cardiovascular Computed Tomography (SCCT). Endorsed by the International Cardio-Oncology Society (ICOS)","volume":"17","author":"Yang","year":"2023","journal-title":"J. Cardiovasc. Comput. Tomogr."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"3233","DOI":"10.1016\/j.jacc.2018.09.051","article-title":"Impact of Statins on Cardiovascular Outcomes Following Coronary Artery Calcium Scoring","volume":"72","author":"Mitchell","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_110","first-page":"100129","article-title":"Artificial intelligence opportunities in cardio-oncology: Overview with spotlight on electrocardiography","volume":"15","author":"Martinez","year":"2022","journal-title":"Am. Heart J. Plus"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/S0140-6736(19)31721-0","article-title":"An artificial intelligence-enabled ECG algorithm for the identification of patients with atrial fibrillation during sinus rhythm: A retrospective analysis of outcome prediction","volume":"394","author":"Attia","year":"2019","journal-title":"Lancet"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.15420\/aer.2022.31","article-title":"Artificial Intelligence for the Detection and Treatment of Atrial Fibrillation","volume":"12","author":"Harmon","year":"2023","journal-title":"Arrhythm. Electrophysiol. Rev."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"e106","DOI":"10.2459\/JCM.0000000000001431","article-title":"Artificial intelligence in cardiovascular prevention: New ways will open new doors","volume":"24","author":"Ciccarelli","year":"2023","journal-title":"J. Cardiovasc. Med."},{"key":"ref_114","first-page":"100126","article-title":"Artificial intelligence and imaging: Opportunities in cardio-oncology","volume":"15","author":"Madan","year":"2022","journal-title":"Am. Heart J. Plus"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00204-022-03341-y","article-title":"An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline","volume":"96","author":"Chang","year":"2022","journal-title":"Arch. Toxicol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"e019628","DOI":"10.1161\/JAHA.120.019628","article-title":"Machine Learning-Based Risk Assessment for Cancer Therapy-Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients","volume":"9","author":"Zhou","year":"2020","journal-title":"J. Am. Heart Assoc."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1007\/s12012-021-09708-4","article-title":"Using Machine Learning Approaches to Predict Short-Term Risk of Cardiotoxicity Among Patients with Colorectal Cancer After Starting Fluoropyrimidine-Based Chemotherapy","volume":"22","author":"Li","year":"2022","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1038\/s41467-024-45733-x","article-title":"Artificial intelligence-enabled prediction of chemotherapy-induced cardiotoxicity from baseline electrocardiograms","volume":"15","author":"Yagi","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jacc.2011.05.025","article-title":"Efficiency of Atorvastatin in the Protection of Anthracycline-Induced Cardiomyopathy","volume":"58","author":"Acar","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-Oncology Rehabilitation to Manage Cardiovascular Outcomes in Cancer Patients and Survivors: A Scientific Statement From the American Heart Association","volume":"139","author":"Gilchrist","year":"2019","journal-title":"Circulation"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1177\/2047487319874900","article-title":"The benefits of exercise in cancer patients and the criteria for exercise prescription in cardio-oncology","volume":"28","author":"Anselmi","year":"2021","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1093\/eurjpc\/zwab006","article-title":"The role of exercise in the prevention of cancer therapy-related cardiac dysfunction in breast cancer patients undergoing chemotherapy: Systematic review","volume":"29","author":"Murray","year":"2022","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1200\/JCO.2017.77.5809","article-title":"Efficacy of Exercise Therapy on Cardiorespiratory Fitness in Patients With Cancer: A Systematic Review and Meta-Analysis","volume":"36","author":"Scott","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s11739-020-02508-8","article-title":"Prevention of anthracycline-induced cardiotoxicity: A systematic review and meta-analysis","volume":"16","author":"Caspani","year":"2021","journal-title":"Intern. Emerg. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"104577","DOI":"10.1016\/j.phrs.2019.104577","article-title":"Role of cardioprotective agents on chemotherapy-induced heart failure: A systematic review and network meta-analysis of randomized controlled trials","volume":"151","author":"Li","year":"2020","journal-title":"Pharmacol. Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"131219","DOI":"10.1016\/j.ijcard.2023.131219","article-title":"Statins as preventive therapy for anthracycline cardiotoxicity: A meta-analysis of randomized controlled trials","volume":"391","author":"Laborante","year":"2023","journal-title":"Int. J. Cardiol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"EVIDoa2200097","DOI":"10.1056\/EVIDoa2200097","article-title":"Statins and Left Ventricular Ejection Fraction Following Doxorubicin Treatment","volume":"1","author":"Hundley","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1001\/jama.2023.11887","article-title":"Atorvastatin for Anthracycline-Associated Cardiac Dysfunction: The STOP-CA Randomized Clinical Trial","volume":"330","author":"Neilan","year":"2023","journal-title":"JAMA"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.jcmg.2022.10.010","article-title":"Cardioprotection Using Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy: 3-Year Results of the SUCCOUR Trial","volume":"16","author":"Negishi","year":"2023","journal-title":"JACC Cardiovasc. Imaging"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_131","first-page":"24","article-title":"Use of Sacubitril\/valsartan in patients with cardio toxicity and heart failure due to chemotherapy","volume":"6","author":"Gregorietti","year":"2020","journal-title":"Cardiooncology"},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Kim, D., Jang, G., Hwang, J., Wei, X., Kim, H., Son, J., Rhee, S.J., Yun, K.H., Oh, S.K., and Oh, C.M. (2022). Combined Therapy of Low-Dose Angiotensin Receptor-Neprilysin Inhibitor and Sodium-Glucose Cotransporter-2 Inhibitor Prevents Doxorubicin-Induced Cardiac Dysfunction in Rodent Model with Minimal Adverse Effects. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122629"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jaccao.2023.03.011","article-title":"The Association of Sodium-Glucose Cotransporter 2 Inhibitors With Cardiovascular Outcomes in Anthracycline-Treated Patients With Cancer","volume":"5","author":"Carrasco","year":"2023","journal-title":"JACC CardioOncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"102350","DOI":"10.1016\/j.cpcardiol.2023.102350","article-title":"Guarding the heart: How SGLT-2 inhibitors protect against chemotherapy-induced cardiotoxicity: SGLT-2 inhibitors and chemotherapy-induced cardiotoxicity","volume":"49","author":"Vafa","year":"2024","journal-title":"Curr. Probl. Cardiol."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/13\/3714\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:04:31Z","timestamp":1760108671000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/13\/3714"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,26]]},"references-count":134,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["jcm13133714"],"URL":"https:\/\/doi.org\/10.3390\/jcm13133714","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,26]]}}}